Impact of the UGT1A1*28 Allele on Response to Irinotecan: A Systematic Review and Meta-analysis

• Hoskins JM , GoldbergRM, QuP, IbrahimJG, McleodHL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl. Cancer Inst.99(17) , 1290–1295 (2007).
   PubMedGoogle Scholar
• Palomaki GE , BradleyLA, DouglasMP, KolorK, DotsonWD. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet. Med.11(1) , 21–34 (2009).
   PubMed Web of Science ®Google Scholar
• Hu ZY , YuQ, ZhaoYS. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Eur. J. Cancer46(10) , 1856–1865 (2010).
   PubMed Web of Science ®Google Scholar
• Hu ZY , YuQ, PeiQ, GuoC. Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin. Cancer Res.16(15) , 3832–3842 (2010).
   PubMed Web of Science ®Google Scholar
• Innocenti F , RatainM. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics7(8) , 1211–1221 (2006).
   PubMed Web of Science ®Google Scholar
• Hoskins JM , McleodHL. UGT1A and irinotecan toxicity: keeping it in the family. J. Clin. Oncol.27(15) , 2419–2421 (2009).
   PubMed Web of Science ®Google Scholar
• Deeken JF , SlackR, MarshallJL. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics – to test or not to test, that is the question. Cancer113(7) , 1502–1510 (2008).
   PubMed Web of Science ®Google Scholar
• Winder T , Lenz H-J. Molecular predictive and prognostic markers in colon cancer. Cancer Treat. Rev.36 , 550–556 (2010).
   PubMed Web of Science ®Google Scholar
• Berg AO , ArmstrongK, BotkinJ et al. Recommendations from the EGAPP working group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?. Genet. Med. 11(1) , 15–20 (2009).
   PubMed Web of Science ®Google Scholar
• Gold HT , HallMJ, BlinderV, SchackmanBR. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer115(17) , 3858–3867 (2009).
   PubMed Web of Science ®Google Scholar
• Obradovic M , MrharA, KosM. Cost–effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. Pharmacogenomics9(5) , 539–549 (2008).
   PubMed Web of Science ®Google Scholar
• Kim H , SeoB, KimJ et al. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase, and uridine diphosphate glucuronosyltransferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. Presented at: Annual Meeting of ASCO. FL, USA, 29 May–2 June 2009.
   Google Scholar
• Braun MS , RichmanSD, QuirkeP et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J. Clin. Oncol. 26(16) , 2690–2698 (2008).
   PubMed Web of Science ®Google Scholar
• Marcuello E , AltesA, MenoyoA, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer91(4) , 678–682 (2004).
   PubMed Web of Science ®Google Scholar
• Boige V , MendiboureJ, PignonJP et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000–2005. J. Clin. Oncol. 28(15) , 2556–2564 (2010).
   PubMedGoogle Scholar
• Kweekel DM , GelderblomH, van der Straaten T et al.UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br. J. Cancer99(2) , 275–282 (2008).
   PubMed Web of Science ®Google Scholar
• McLeod HL , SargentDJ, MarshS et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from north American gastrointestinal intergroup trial N9741. J. Clin. Oncol. 28(20) , 3227–3233 (2010).
   PubMed Web of Science ®Google Scholar
• Martinez-Balibrea E , AbadA, Martinez-CardsA et al. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br. J. Cancer103(4) , 581–589 (2010).
   PubMed Web of Science ®Google Scholar
• Ruzzo A , GrazianoF, LoupakisF et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J. 8(4) , 278–288 (2008).
   PubMed Web of Science ®Google Scholar
• Sugiyama T , HiroseT, KusumotoS et al. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer. Oncol. Res. 18(7) , 337–342 (2009).
   Web of Science ®Google Scholar
• Toffoli G , CecchinE, CoronaG et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol. 24(19) , 3061–3068 (2006).
   PubMed Web of Science ®Google Scholar
• Han JY , LimHS, ShinES et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24(15) , 2237–2244 (2006).
   PubMed Web of Science ®Google Scholar
• Carlini LE , MeropolNJ, BeverJ et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin. Cancer Res.11(3) , 1226–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Glimelius B , GarmoH, BerglundA et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J. 11(1) , 61–71 (2011).
   PubMed Web of Science ®Google Scholar
• Lara Jr PN , NataleR, CrowleyJ et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J. Clin. Oncol. 27(15) , 2530–2535 (2009).
   PubMed Web of Science ®Google Scholar
• Pillot GA , ReadWL, HennenfentKL et al. A Phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J. Thorac. Oncol. 1(9) , 972–978 (2006).
   PubMed Web of Science ®Google Scholar
• Liu CY , ChenPM, ChiouTJ et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer112(9) , 1932–1940 (2008).
   PubMed Web of Science ®Google Scholar
• Schulz C , HeinemannV, SchalhornA et al. UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World J. Gastroenterol.15(40) , 5058–5066 (2009).
   PubMed Web of Science ®Google Scholar
• Takano M , KatoM, YoshikawaT et al. Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers. Oncology 76(5) , 315–321 (2009).
   PubMed Web of Science ®Google Scholar
• Fuse N , SuenagaM, YamaguchiT et al. First evaluation of the efficacy, safety, and drug–drug interaction of combination therapy of FOLFIRI and bevacizumab in UGT1A1 gene polymorphism of advanced and recurrent colorectal cancer. Presented at: 12th World Congress on Gastrointestinal Cancer, ESMO. Barcelona, Spain, 30 June–3 July 2010.
   Google Scholar
• Moher D , LiberatiA, TetzlaffJ, AltmanD. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med.6(7) , 1–6 (2009).
   Web of Science ®Google Scholar
• Liberati A , AltmanD, TetzlaffJ et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 6(7) , 1–28 (2009).
   Web of Science ®Google Scholar
• Stroup D , BerlinJ, MortonS et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283(15) , 2008–2012 (2000).
   PubMed Web of Science ®Google Scholar
• Jorgensen AL , WilliamsonPR. Methodological quality of pharmacogenetic studies: issues of concern. Stat. Med.27 , 6547–6569 (2008).
   PubMed Web of Science ®Google Scholar
• Cecchin E , InnocentiF, D‘AndreaM et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J. Clin. Oncol. 27(15) , 2457–2465 (2009).
   PubMed Web of Science ®Google Scholar
• Enzinger P , FidiasP, ReganE et al. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. Presented at: 34th Congress of the European Society for Medical Oncology (ESMO). Stockholm, Sweden, 12–16 September 2008.
   Google Scholar
• Etienne-Grimaldi M , BennounaJ, FormentoJ et al. Prospective pharmacogenetic analysis in advanced colorectal cancer (CRC) patients receiving first-line cetuximab–UFT–irinotecan therapy: importance of gene polymorphisms related to antibody-dependent cellular cytotoxicity (ADCC). Presented at: Annual Meeting of ASCO. FL, USA, 29 May–2 June 2009.
   Google Scholar
• Gamulin M , JokicM, GrgicM, KapitanovicS. Pharmacogenetic database of colorectal cancer patients in croatia – correlation with clinical data. Presented at: 34th Congress of the European Society for Medical Oncology (ESMO). Stockholm, Sweden, 12–16 September 2008.
   Google Scholar
• Kularatne B , MarinakiA, SpicerJ, LoganayagamA, RossP. Pharmacogenetics of irinotecan: minimising toxicities and maximising clinical response. Presented at: 5th European Multidisciplinary Colorectal Cancer Congress EMCC. Nice, France, 28–30 March 2010.
   Google Scholar
• Yang D , PohlA, ZhangW et al. Pharmacogenetic analysis in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line irinotecan (IR)+/- cetuximab (CB): The EPIC experience. Presented at: Annual Meeting of ASCO. FL, USA, 29 May–2 June 2009.
   Google Scholar
• Zarate RN , RodriguezJ, BandresE et al. Predictive value of Ile105Val polymorphism of the gluthatione-S-transferase P1 in patients with metastatic colorectal cancer (mCRC) treated with the triplet combination of irinotecan, oxaliplatin, and capecitabine. Presented at: Annual Meeting of ASCO. FL, USA, 29 May–2 June 2009.
   Google Scholar
• Martinez-Balibrea E , AbadA, ValladaresM et al. Pharmacogenetic analysis of TS and UGT1A polymorphisms predictive for response and toxicity in Spanish patients with advanced colorectal cancer treated with first-line irinotecan and 5-fluorouracil. Presented at: Annual Meeting of ASCO. FL, USA, 29 May–2 June 2009.
   Google Scholar
• Michaelis L , RatainM. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat. Rev. Cancer6 , 409–414 (2006).
   PubMed Web of Science ®Google Scholar
• Weber W . Assessing tumor response to therapy. J. Nucl. Med.50(Suppl. 5) , 1S–10S (2009).
   PubMed Web of Science ®Google Scholar
• Wu W , SargentD. Choice of endpoints in cancer clinical trials. In: Oncology Clinical Trials: Successful Design, Conduct, and Analysis. Kelly W, Halabi S (Eds). Demos Medical Publishing, NY, USA, 35–42 (2010).
   Google Scholar
• De Roock W , ClaesB, BernasconiD et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11 , 753–762 (2010).
   PubMed Web of Science ®Google Scholar
• Font A , SanchezJM, TaronM et al. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest. New Drugs 21(4) , 435–443 (2003).
   PubMed Web of Science ®Google Scholar

▪ Websites

• West S, King V, Carey T et al. Systems to rate the strength of scientific evidence. In: Evidence Report/Technology Assessment No. 47, A.H.R.Q. (Ed.). Research Triangle Institute – University of North Carolina, Evidence-based Practice Center, Rockville, MD, USA, 1–200 (2002). www.thecre.com/pdf/ahrq-system-strength.pdf
   Google Scholar
• Review Manager (RevMan) [Computer Program]. Version 5.1. (2011). http://ims.cochrane.org/revman
   Google Scholar
• Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta-analysis, Version 2, Biostat. (2005). www.meta-analysis.com
   Google Scholar